Hong Kong Stock Rating Summary | HSBC Research maintains a 'Buy' rating on Alibaba.

Major financial institutions have issued updated ratings and target prices for key Hong Kong-listed companies. HSBC Research raised Alibaba's H-share target to HKD 156, maintaining a Buy, on robust cloud performance. However, UBS Group cut BYD Company's target to HKD 160 due to a weaker Q2 and slow Q3 outlook, while Credit Suisse downgraded ZTE to Underperform, citing disappointing margins and unattractive valuation. Concurrently, firms like CMB International, DBS Bank, Citi Research, and CICC provided positive updates and raised targets for Innovent Bio, Horizonrobot, BYD Electronics, Xindong Company, Zijin Mining, Yadea Holdings, and AK Medical, reflecting strong financial results and favorable sector trends.

Analysis

A review of analyst ratings on September 1 reveals a significant divergence in institutional outlook across key Hong Kong-listed sectors. In technology, Alibaba (09988.HK) received a bullish update from HSBC, which raised its target price to HKD 156, citing an improved outlook for its cloud business and an increased CMR growth forecast from 7% to 9% for fiscal year 2026. Conversely, Credit Suisse downgraded ZTE Corporation (00763.HK) to Underperform due to a Q2 gross margin decline and unattractive valuation, with profit forecasts 26-31% below market expectations. The automotive space shows a clear split: while BYD Company (01211.HK) saw its target price cut to HKD 160 by UBS following a Q2 performance miss and a 30% reduction in its 2025 earnings forecast, its affiliate BYD Electronics (00285.HK) had its target raised to HKD 52.9 by Citi on expected growth from the automotive sector. Other notable positive updates include Innovent Bio (01801.HK), which saw its H1 2025 product revenue grow 37% year-on-year, and Xindong Company (02400.HK), with an expected 268% year-on-year increase in H1 2025 net profit, reflecting strong fundamental performance in the biotech and gaming sectors respectively.

Key Decisions for Investors

• Investors should note the positive reinforcement for Alibaba, where HSBC's raised target to HKD 156 on the back of improving cloud and CMR metrics provides fundamental support for a continued long position.
• It is crucial to differentiate between BYD Company (01211.HK), which faces significant near-term margin pressure and downward earnings revisions, and BYD Electronics (00285.HK), which has a more favorable outlook according to Citi.
• The downgrade of ZTE Corporation to Underperform by Credit Suisse, citing a performance miss and a valuation deemed unattractive against a negative profit growth outlook, warrants a cautious stance and a review of existing positions.
• High-growth sectors like biotech and gaming show strong momentum, with Innovent Bio's 37% revenue growth and Xindong's 268% profit surge highlighting opportunities in companies with robust execution and clear commercialization pipelines.